Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Holding RYTM?
Track your performance easily
RYTM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.53 - $68.58
Previous Close$56.23
Volume690.31K
Average Volume (3M)479.58K
Market Cap
$3.46B
Enterprise Value$3.16B
Total Cash (Recent Filing)$298.39M
Total Debt (Recent Filing)$4.03M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 04, 2025EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding61,457,069
10 Day Avg. Volume1,005,182
30 Day Avg. Volume479,577
Standard Deviation0.35
R-Squared0.10
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)87.86
Price to Sales (P/S)36.09
Price to Cash Flow (P/CF)-31.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue28.09
Enterprise Value/Gross Profit46.40
Enterprise Value/Ebitda-15.48
Forecast
1Y Price Target
$67.18Price Target Upside19.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Rhythm Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $31.52 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.805 by $0.075.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -$0.75.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 61,457,070 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.805. Following the earnings report the stock price went up 11.378%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Among the largest hedge funds holding Rhythm Pharmaceuticals Inc’s share is PRIMECAP Management Co. It holds Rhythm Pharmaceuticals Inc’s shares valued at 378M.
---
Rhythm Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.18 (19.47% Upside)
$67.18 (19.47% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 95.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.33%
12-Months-Change
Fundamentals
Return on Equity
-248.12%
Trailing 12-Months
Asset Growth
2.65%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q3 2024
0:00 / 0:00
---
RYTM Stock 12 Month Forecast
Average Price Target
$67.18
▲(19.47% Upside)
Technical Analysis
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+66.37%
reiterated a buy rating 17 days ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +66.37% per trade.
---